Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. - Wikidata - awgldk - TriplyDB

Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance.

Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance.

http://www.wikidata.org/entity/Q35452357

about

Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidence High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in Tanzania Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis Antimalarial drugs for preventing malaria during pregnancy and the risk of low birth weight: a systematic review and meta-analysis of randomized and quasi-randomized trials Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy Efficacy of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, Zambia Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles Increasing prevalence of a novel triple-mutant dihydropteroate synthase genotype in Plasmodium falciparum in western Kenya Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin, on PCR-diagnosed malaria at delivery: a randomized controlled trial Independent lineages of highly sulfadoxine-resistant Plasmodium falciparum haplotypes, eastern Africa.Pregnancy-associated malaria and malaria in infants: an old problem with present consequences Community-based scheduled screening and treatment of malaria in pregnancy for improved maternal and infant health in The Gambia, Burkina Faso and Benin: study protocol for a randomized controlled trial Intermittent use of sulphadoxine-pyrimethamine for malaria prevention: a cross-sectional study of knowledge and practices among Ugandan women attending an urban antenatal clinic.Coverage and efficacy of intermittent preventive treatment with sulphadoxine pyrimethamine against malaria in pregnancy in Côte d'Ivoire five years after its implementation.Uptake of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in Geita district, North-Western Tanzania.Evaluation of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a retrospective birth outcomes study in Mansa, Zambia.Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.Intermittent presumptive treatment in pregnancy with sulfadoxine-pyrimethamine: a counter perspective Adaptive evolution and fixation of drug-resistant Plasmodium falciparum genotypes in pregnancy-associated malaria: 9-year results from the QuEERPAM study Does Iron Increase the Risk of Malaria in Pregnancy?Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya.Lack of effect of intermittent preventive treatment for malaria in pregnancy and intense drug resistance in western Uganda.Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy given sulphadoxine-pyrimethamine resistance in Africa: A mathematical model.Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study.Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi.Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria.Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study The Performance of a Rapid Diagnostic Test in Detecting Malaria Infection in Pregnant Women and the Impact of Missed Infections Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.Malaria risk factors in women on intermittent preventive treatment at delivery and their effects on pregnancy outcome in Sanaga-Maritime, Cameroon.

P2860

Q21032450-8150BD55-636E-4318-9F80-C25668D122FC Q21033803-9A6D32E3-31DB-4BD5-83A1-F09213055C9D Q26795623-84AB3830-E532-4FC7-BF13-FB822E383C25 Q26798114-AE7C4D48-6BAA-4C60-AFDA-12B8E347C8C9 Q26849714-B2F674D1-9DFF-4F37-A829-F3944EEB4410 Q27005614-FE70E4B0-22EE-40FF-9AC8-D9E8B9CA92CD Q28125905-8D49868E-3E88-4625-96EA-5E7D9B855FA4 Q28125916-3FFC2FC2-4D0D-4307-B14C-3C7AA8DA32B2 Q28125918-3DBEAD73-C57E-4AC6-BB15-C6E8378A1237 Q28125923-451DF723-6062-4DF4-8ACE-4585BC94CA81 Q28125930-4D236028-E0D1-41E1-A771-B1430F8E7595 Q28125938-2FAA4BAF-37BC-4C85-8D67-818E9FC44A5B Q28477515-EBA01570-786B-4552-8E77-5669EAD74073 Q28486791-ECB5BBBA-A056-435D-9D35-D93D3A7076BA Q28536733-3B7A94C7-D3E9-4568-BD18-446D6F1450C7 Q28541598-37E3D3D9-BE42-4E5D-AF41-C09E0077EB17 Q28729015-7F547BB4-68BE-4A28-8CE5-D76B6AD26505 Q33816411-7665B461-68C0-4F1C-9FF6-1CA48A6C13B1 Q33963392-830A2503-E3E5-4CF8-9825-0A4E26043593 Q34143715-AD8B2EA3-467F-4331-BDC7-ADAA07478598 Q34410295-BB51B203-B9BE-487C-8C54-A026F84DAD3D Q34579161-0D79E425-BBF1-4C81-ADE4-EFEC662F474A Q34637039-24F0A388-D6EF-4546-B83F-DC0BF3865058 Q35082469-C8BFE093-2663-4A3E-8562-0F519E0DB491 Q35356543-DD04CD12-95E1-4467-B5FD-179959B68248 Q35619781-56D58B99-BE04-4AC1-8B84-F68229015AE2 Q35741292-E88C3857-B847-4341-8E91-0BD6A7DC7E38 Q35759333-8896E8AB-03A0-4418-81B8-40D7589F9415 Q35802773-F7AC0DE7-4DA8-4A5E-98D6-1955575BD5C8 Q36051953-CF45728C-0F63-4DB0-ACA5-A8EB24D07F99 Q36077922-1A1D6F7A-80F4-4C29-A17C-2FC81A95EF90 Q36094714-C6B5F24E-0D80-4B53-AA83-F13802E6DF5A Q36292865-50C23101-E79D-437E-87C6-F261488EC28F Q36461809-EE04E5F7-7E40-4D5B-A52F-4788D4C165FA Q36466975-3F838F0E-EF1E-4027-B34F-44C328C93E2F Q36556994-B369571B-40E2-49C2-9DE3-858FB6AE76F1 Q36612898-160B0936-73DD-4999-8AE5-A214EC046863 Q36676359-7087619F-D5FF-4300-A679-7BF5A4165CD6 Q36843561-A21F1A99-F10E-403D-B18A-1F6E52CA6177 Q36908893-E505DE3B-F0B0-41BD-9AA3-BBECBB3BF4ED

P2860

Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance.

http://www.wikidata.org/entity/Q35452357

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Intermittent treatment to prev ...... of widespread drug resistance.

@ast

Intermittent treatment to prev ...... of widespread drug resistance.

@en

type

label

Intermittent treatment to prev ...... of widespread drug resistance.

@ast

Intermittent treatment to prev ...... of widespread drug resistance.

@en

prefLabel

Intermittent treatment to prev ...... of widespread drug resistance.

@ast

Intermittent treatment to prev ...... of widespread drug resistance.

@en

P1433

Q35452357-A861A897-F322-4DE0-8342-75BD5DBCC38F

P1476

Q35452357-CC887039-A4F7-428E-A75E-FF2E5EA70162

P2093

Q35452357-5539C259-1D2F-4A38-825B-911EBFF2E528

Q35452357-D8878945-DE84-4D4B-9414-389E1D67CD4C

Q35452357-DC681534-3C39-434E-946A-1F67476113EF

Q35452357-F3748FF5-C17A-4782-A42A-CF764D4916D3

P2860

Q35452357-19B72C1D-4C9E-43E6-A388-3A2DA6250045

Q35452357-1E5210DC-262C-454A-BB50-47BAFF93E6BF

Q35452357-36C55D42-5384-4353-9C86-BE953F21AA61

Q35452357-3E241E1C-927F-4DB9-93F9-5673294EF8F2

Q35452357-41CA5977-834C-4D42-A2DF-65D6362B0ACD

Q35452357-4510D503-62DF-4531-A2D9-883401A4220E

Q35452357-46363022-5FD7-4427-AE1E-E40A35FE404A

Q35452357-527016C1-3182-4BE6-B709-F41A2C891A5F

Q35452357-54970DF3-18BE-40F6-AAAC-F5E9CA046F34

Q35452357-5EF7FAD8-9BC5-4061-89D5-B0294C73D33F

P304

Q35452357-9FD63615-83D3-419C-9126-F279031E39E0

P31

Q35452357-FD51DD62-6DAB-4646-9D0D-670288EA64A8

P356

Q35452357-3CC10386-3D0E-4B72-88E5-2C5FFAC8520D

P407

Q35452357-94041499-1253-442E-8D2A-29F1DAB9A658

P433

Q35452357-473A8F89-D1D9-4C31-BADF-1B49B852CCE6

P478

Q35452357-43369960-2240-4A66-B15E-B90E48FC78AF

P50

Q35452357-B48E40A8-AD15-45B6-BA5B-391749C24756

P577

Q35452357-EEF8414A-019A-4B8F-8C77-5CD418DA4DC3

P5875

Q35452357-E70C965A-3EDA-4E61-9852-FF76397DA29D

P698

Q35452357-69F0271D-9609-4693-9089-50B4815256C3

P921

Q35452357-59C4A8B7-49E7-4C44-9577-54B87F9AFFE9

Q35452357-BC001B9B-12C1-4913-A5B9-680AA1F2822B

Q35452357-C139BA2D-DF79-4C68-BBAB-9BDCABA5D63A

P932

Q35452357-0CED79B7-90E5-4514-8C17-FC7B088EA9F2

P356

P1433

Clinical Infectious Diseases

P1476

Intermittent treatment to prev ...... of widespread drug resistance.

@en

P2093

Edward Kabyemela

http://www.w3.org/2001/XMLSchema#string

Michal Fried

http://www.w3.org/2001/XMLSchema#string

Theonest K Mutabingwa

http://www.w3.org/2001/XMLSchema#string

Whitney E Harrington

http://www.w3.org/2001/XMLSchema#string

P2860

Maternal malaria and gravidity interact to modify infant susceptibility to malaria.

High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581

Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review.

A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic.

Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic.

Plasmodium infection and its risk factors in eastern Uganda.

An analysis of anemia and child mortality.

Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.

Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa.

Fetal anaemia in malarious areas: its causes and significance.

P304

224-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIR376

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Patrick E. Duffy

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51498339

http://www.w3.org/2001/XMLSchema#string

P698

21765070

http://www.w3.org/2001/XMLSchema#string

P921

pregnancy-associated malaria

malaria prevention

P932

3202321

http://www.w3.org/2001/XMLSchema#string